{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470629578
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = [[Vascular adhesion protein|VAP-1]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 195158-85-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Vepalimomab''' is a [[mouse]] [[monoclonal antibody]] developed for the treatment of [[inflammation]]s. It blocks the [[vascular adhesion protein 1]].<ref>{{cite journal
| year=2005
| last1=Vainio |first1=PJ
| last2=Kortekangas-Savolainen |first2=O
| last3=Mikkola |first3=JH
| last4=Jaakkola |first4=K
| last5=Kalimo |first5=K
| last6=Jalkanen |first6=S
| last7=Veromaa |first7=T
| title=Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis
| journal=[[Basic & Clinical Pharmacology & Toxicology]]
| volume=96 |issue=6 |pages=429â€“35
| doi=10.1111/j.1742-7843.2005.pto_05.x
| pmid=15910406
}}</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}